Non-steroidal anti-inflammatory drugs as disease-modifying agents for Parkinson's disease: evidence from observational studies - PubMed (original) (raw)

Review

Non-steroidal anti-inflammatory drugs as disease-modifying agents for Parkinson's disease: evidence from observational studies

Karen Rees et al. Cochrane Database Syst Rev. 2011.

Abstract

Background: Neuroinflammation may play a key role in the neurodegeneration associated with Parkinson's disease (PD). Non-steroidal anti-inflammatory drugs (NSAIDs) may be beneficial in the primary and secondary prevention of PD.

Objectives: 1) Do NSAIDs prevent the onset of PD?2) Are NSAIDs neuroprotective in PD - do they slow the progression of disease once PD is established?3) What are the adverse effects of taking NSAIDs in PD?

Search methods: We searched electronic databases, including trial registers, complemented with handsearching of conference proceedings and citation searching on key articles. All searching was updated in May 2011. We contacted authors to provide additional information where necessary.

Selection criteria: For the primary prevention review, we sought primary prevention trials and observational studies (cohort and case-control studies). Participants were free of PD when exposure to NSAIDs was assessed. For the secondary prevention review, we sought clinical trials in patients with a well-defined definition of PD. Two people independently selected studies for inclusion using predetermined criteria.

Data collection and analysis: Two review authors abstracted data from the source papers and assessed methodological quality independently. No studies met the inclusion criteria for the secondary prevention review. For the primary prevention review only observational studies were found. We combined data where appropriate using the inverse variance method. We assessed methodological quality using the Newcastle Ottawa Scales and by examining the period of exposure assessed prior to PD onset (or the index date in controls).

Main results: Fourteen observational studies met the inclusion criteria for the primary prevention review (five cohort, nine case-control studies). Exposure to any NSAIDs or aspirin had no effect on the risk of developing PD. Exposure to non-aspirin NSAIDs reduced the risk of developing PD by 13% (effect estimate 0.87 (95% CI 0.73 to 1.04 - random-effects model), but this did not reach statistical significance. We found similar results for the most robust studies. Ibuprofen in isolation was examined in four studies and was associated with a 27% reduction in risk (effect estimate 0.73, 95% CI 0.63 to 0.85). There was a lack of information on adverse effects.

Authors' conclusions: There is currently no evidence for the use of NSAIDs in the secondary prevention of PD. Non-aspirin NSAIDs, particularly ibuprofen, may reduce the risk of developing PD. However, little is known of the effects of other individual drugs and at present no recommendations can be made regarding their use in primary prevention.

PubMed Disclaimer

Cited by

A systematic review and meta-analysis of inflammatory biomarkers in Parkinson's disease.
Qu Y, Li J, Qin Q, Wang D, Zhao J, An K, Mao Z, Min Z, Xiong Y, Li J, Xue Z. Qu Y, et al. NPJ Parkinsons Dis. 2023 Feb 4;9(1):18. doi: 10.1038/s41531-023-00449-5. NPJ Parkinsons Dis. 2023. PMID: 36739284 Free PMC article. Review.
Reformulating Pro-Oxidant Microglia in Neurodegeneration.
García-Revilla J, Alonso-Bellido IM, Burguillos MA, Herrera AJ, Espinosa-Oliva AM, Ruiz R, Cruz-Hernández L, García-Domínguez I, Roca-Ceballos MA, Santiago M, Rodríguez-Gómez JA, Soto MS, de Pablos RM, Venero JL. García-Revilla J, et al. J Clin Med. 2019 Oct 17;8(10):1719. doi: 10.3390/jcm8101719. J Clin Med. 2019. PMID: 31627485 Free PMC article. Review.
C-Reactive Protein and Risk of Parkinson's Disease: A Systematic Review and Meta-Analysis.
Qiu X, Xiao Y, Wu J, Gan L, Huang Y, Wang J. Qiu X, et al. Front Neurol. 2019 Apr 17;10:384. doi: 10.3389/fneur.2019.00384. eCollection 2019. Front Neurol. 2019. PMID: 31057478 Free PMC article.
Drug repurposing strategies of relevance for Parkinson's disease.
Fletcher EJR, Kaminski T, Williams G, Duty S. Fletcher EJR, et al. Pharmacol Res Perspect. 2021 Aug;9(4):e00841. doi: 10.1002/prp2.841. Pharmacol Res Perspect. 2021. PMID: 34309236 Free PMC article. Review.
The Ageing Brain: Molecular and Cellular Basis of Neurodegeneration.
Azam S, Haque ME, Balakrishnan R, Kim IS, Choi DK. Azam S, et al. Front Cell Dev Biol. 2021 Aug 13;9:683459. doi: 10.3389/fcell.2021.683459. eCollection 2021. Front Cell Dev Biol. 2021. PMID: 34485280 Free PMC article. Review.

Non-steroidal anti-inflammatory drugs as disease-modifying agents for Parkinson's disease: evidence from observational studies - PubMed (original) (raw)